A Phase II Study Evaluating the Interest to Combine UCPVax a CD4 TH1-inducer Cancer Vaccine and Atezolizumab for the Treatment of Human PapillomaVirus Positive Cancers
Latest Information Update: 26 Dec 2024
At a glance
- Drugs Atezolizumab (Primary) ; HTERT peptide vaccine-Invectys (Primary)
- Indications Anal cancer; Cervical cancer; Head and neck cancer; Squamous cell cancer; Vulvovaginal cancer
- Focus Therapeutic Use
- Acronyms VolATIL
Most Recent Events
- 10 Mar 2024 According to an European Clinical Trials Database, this trial has been completed in France
- 10 Mar 2024 Status changed from active, no longer recruiting to completed.
- 25 May 2023 Status changed from recruiting to active, no longer recruiting.